{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Alonso-Solis A"],"funding":["H2020 European Institute of Innovation and Technology"],"pubmed_abstract":["<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia <b>(</b>m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a"],"journal":["BMJ open"],"pagination":["e021346"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6082494"],"repository":["biostudies-literature"],"pubmed_title":["Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers."],"pmcid":["PMC6082494"],"pubmed_authors":["Alcalde F","Papas I","Coenen T","Rubinstein K","Tauro V","Triantafillou A","Koponen HJ","Ochoa S","Unoka Z","Vita I","Escobar M","Isohanni M","Almazan C","Simonetti V","Marco-Garcia S","Rubio-Abadal E","D'amico E","Jewel C","Mentzas G","Kokkinakis P","Jamsa T","Huerta-Ramos E","Usall J","Vella VA","Bitter I","Kaye R","Bugheroni M","Grasa EM","Stevens M","Caro-Mendivelso J","Roldan A","Juola T","Keymer-Gausset A","Hospedales M","Reixach E","m-Resist group","Farkas K","Gimenez E","Caspi A","Van der Graff S","Moilanen J","Seppala J","Alonso-Solis A","Baccinelli W","Fazekas K","Seppala A","Jaaskelainen E","Constant X","Sebu G","Vermeir D","Bonizzi C","Corripio I","Berdun J","Paraskevopoulos F","Miettunen J"],"additional_accession":[]},"is_claimable":false,"name":"Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.","description":"<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia <b>(</b>m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2026-04-16T17:17:19.707Z","creation":"2019-03-26T23:50:57Z"},"accession":"S-EPMC6082494","cross_references":{"pubmed":["30012788"],"doi":["10.1136/bmjopen-2017-021346"]}}